Airway microvascular extravasation and luminal entry of plasma

Clinical Physiology and Functional Imaging

Volumn 23, Issue 6, 2003, Pages 301-306

  Greiff, Lennart ^a   Andersson, Morgan ^a   Erjefält, Jonas S ^a   Persson, Carl G A ^a   Wollmer, Per ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Asthma; Bronchial; Exudation; Inflammation; Nasal; Rhinitis

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BINDING PROTEIN; BUDESONIDE; FORMOTEROL; GLUCOCORTICOID; IMMUNOGLOBULIN; NITRIC OXIDE DONOR; PLACEBO; PLASMA PROTEIN; PROSTACYCLIN DERIVATIVE; TERBUTALINE;

ALLERGIC RHINITIS; ASTHMA; BRONCHIOLE; CELL JUNCTION; DRUG MECHANISM; EPITHELIUM CELL; EXTRAVASATION; HUMAN; LAMINA PROPRIA; LUNG BLOOD VESSEL; LUNG EXTRAVASCULAR FLUID; MICROVASCULATURE; MUCOSA INFLAMMATION; NONHUMAN; NOSE CAVITY; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN BINDING; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; REVIEW; TISSUE DISTRIBUTION; VENULE;

EID: 0345688717     PISSN: 14750961     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1475-0961.2003.00519.x     Document Type: Review

References (38)

1. Baluk P, McDonald DM. The beta 2-adrenergic receptor antagonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol (1994); 266: L461-468.
2. Berg S, Wollmer P, Morgan Andersson M, Persson CGA, Greiff L. Effects of experimental changes in nasal airway pressure on mucosal output of plasma. Clin Physiol Funct Imaging (2003); 23: 155-158.
3. Bousquet J, Lebel B, Chanal I, Morel A, Michel FB. Antiallergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol (1988); 82: 881-887.
4. Elwood RK, Kennedy S, Belzberg A, Hogg JC, Pare D. Respiratory mucosal permeability in asthma. Am Rev Respir Dis (1983); 128: 523-527.
5. Erjefält JS, Erjefält I, Sundler F, Persson CGA. Mucosal nitric oxide may tonically suppress airways plasma exudation. Am J Respir Crit Care Med (1994); 150: 227-232.
6. Erjefält JS, Erjefält I, Sundler F, Persson CGA. Epithelial pathways for luminal entry of bulk plasma. Clin Exp Allergy (1995); 25: 187-195.
7. Erjefält JS, Sundler F, Persson CGA. Eosinophils, neutrophils and venular gaps in the airway mucosa at epithelial removal-restitution. Am J Respir Crit Care Med (1996); 153: 1666-1674.
8. 51Cr-EDTA across the human nasal mucosa in the presence of topical histamine. Thorax (1991); 146: 630-632.
9. Greiff L, Andersson M, Åkerlund A et al. Microvascular exudative hyperresponsiveness in human coronavirus-induced common cold. Thorax (1994a); 49: 121-127.
10. Greiff L, Andersson M, Svensson C, Alkner U, Persson CGA. Glucocorticoids may not inhibit plasma exudation by direct vascular antipermeability effects in human airways. Eur Resp J (1994b); 7: 1120-1124.
11. Greiff L, Andersson M, Svensson C et al. Topical nitroprusside may reduce histamine-induced plasma exudation in human nasal airways. Allergy (1995); 50: 593-597.
12. Greiff L, Erjefält I, Erjefält JS, Wollmer P, Sundler F, Persson CGA. Effects of topical platelet activating factor on the guinea-pig tracheobronchial mucosa in vivo. Acta Physiol Scand (1997a); 160: 387-391.
13. Greiff L, Lundin S, Svensson C, Andersson M, Wollmer P, Persson CGA. Reduced airway absorption in seasonal allergic rhinitis. Am J Respir Crit Care Med (1997b); 156: 783-786.
14. Greiff L, Wollmer P, Andersson M, Svensson C, Persson CGA. Effects of formoterol on histamine challenge-induced plasma exudation in induced sputum from normal subjects. Thorax (1998); 53: 1010-1013.
15. Greiff L, Persson CGA, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Imummol (2002); 89: 413-418.
16. Greiff L, Andersson M, Erjefält JS, Svensson C, Persson CGA. Loss of size-selectivity at histamine-induced exudation of plasma proteins in human nasal airways. Clin Physiol Funct Imaging (2002a); 22: 28-31.
17. Greiff L, Andersson M, Svensson C et al. Absorption across the mucosa in house dust mite perennial allergic rhinitis. Clin Physiol Funct Imaging (2002b); 22: 55-57.
18. Gustafsson B, Persson CGA. Asymmetrical effects of increases in hydrostatic pressure on macromolecular movement across the airway mucosa. Clin Exp Allergy (1991); 21: 121-126.
19. Jezierski PV. Zur Pathologie des Asthma bronchiale. Deutsche Archiv Klinische Medizin (1906); 85: 342-347.
20. Kobzik L, Bredt DS, Lownstein CJ et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol (1993); 9: 371-377.
21. McDonald DM, Thurston G, Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation (1999); 6: 7-22.
22. Majno G, Palade GE. Studies on inflammation I. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol (1961); 11: 571-605.
23. Majno G, Palade GE, Schoefl GI. Studies on inflammation II. The site of action of histamine and serotonin along the vascular tree: a topographic study. J Biophys Biochem Cytol (1961); 11: 607-626.
24. 2-Macroglobulin and eosinophil cationic protein in the allergic airway mucosa in seasonal allergic rhinitis. Eur Respir J (1999 ); 13: 633-637.
25. Meyer P, Andersson M, Persson CGA, Greiff L. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis. Pediatr Allergy Immunol (2003); 14: 60-65.
26. Miller-Larsson A, Brattsand R. Topical anti-inflammatory activity of the glucocorticoid budesonide on airway mucosa. Evidence for a "hit and run" type of activity. Agents Actions (1990); 29: 127-129.
27. Naclerio RM, Meier HL, Kagey-Sobotka A. et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983); 128: 597-602.
28. Naclerio RM, Kagey-Sobotka A, Lichtenstein LM, Firedhoff L, Proud D. Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis (1990); 142: 167-171.
29. Persson CGA, Erjefält I, Gustafsson B, Luts A. Subepithelial hydrostatic pressure may regulate plasma exudation across the mucosa. Int Arch Allergy Appl Immunol (1990); 92: 148-153.
30. Persson CGA, Erjefält I, Alkner U et al. Plasma exudation as a first line respiratory mucosal defence. Clin Exp Allergy (1991); 21: 17-24.
31. Persson CGA, Erjefält JS, Greiff L et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J (1998); 11: 958-970.
32. 2-macroglobulin. Biochem J (1987); 245: 781-787.
33. Pietra GG, Szidon JP, Leventhal MM, Fishman AP. Histamine and interstitial pulmonary edema in the dog. Circ Res (1971); 29: 323-337.
34. Svensson C, Klementsson H, Andersson M, Pipkorn U, Alkner U, Persson CGA. Glucocorticoid induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergic rhinitis. Allergy (1994); 49: 177-183.
35. Svensson C, Andersson M, Greiff L, Alkner U, Persson CGA. Exudative hyperresponsiveness of the airway microcirculation in seasonal allergic rhinitis. Clin Exp Allergy (1995a); 25: 942-950.
36. Svensson C, Greiff L, Andersson M, Grönneberg R, Persson CGA. Anti-allergic action of high topical doses of terbutaline in human nasal airways. Allergy (1995b); 50: 884-890.
37. Van der Graaf EA, Out TA, Roos CM, Jansen HM. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Am Rev Respir Dis (1991); 143: 362-368.
38. Wihl JA, Mygind N. Studies on the allergen-challenges human nasal mucosa. Acta Otolaryngol (1977); 84: 281-286.